ProBiotix Health PLC
Navigating Financial Waters Amidst External Turbulence
A Financial Odyssey in the World of Probiotics
By Alex Langton | 1 October 2023
I have an investment in ProBiotix Health.
ProBiotix Health has emerged as a notable thread in the intricate tapestry of the life sciences sector, weaving its expertise in developing probiotics to combat cardiovascular diseases and lifestyle conditions. The company's audited results, spanning from its flotation on the AQSE Growth Market on 31 March 2022 to 31 December 2022, offer a panoramic view of its financial landscape, marked by challenges, resilience, and growth.
Setting the Stage: The AQSE Listing
The decision to list ProBiotix on the AQSE market was met with scepticism from some quarters; my father was and still is irked by the decision, including from seasoned observers like Mike and myself. Our reservations, particularly concerning the AQSE's liquidity challenges and the stark bid-offer spread, have deterred new investors from taking a punt, hence the dramatic share-price decline, an event my father warned investors and the CEO Stephen O’Hara would be the result.